Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00530881
NCT00530881
Completed
Phase 2

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Establish Proof of Concept With PHX1149 in Patients With Type 2 Diabetes Mellitus

Phenomix1 site in 1 country180 target enrollmentApril 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsType 2 Diabetes Mellitus
InterventionsPHX1149
DrugsPHX1149

Overview

Phase
Phase 2
Intervention
PHX1149
Conditions
Type 2 Diabetes Mellitus
Sponsor
Phenomix
Enrollment
180
Locations
1
Primary Endpoint
postprandial blood glucose
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

This will be a 4-week, multicenter, randomized, double-blind, parallel group, placebo-controlled, safety, tolerability, and efficacy study. Patients will be screened and be on one of three doses of PHX1149 (a new drug candidate for the treatment of Type 2 diabetes ) or placebo. The drug is a "DPP4 inhibitor"

Registry
clinicaltrials.gov
Start Date
April 2006
End Date
October 2006
Last Updated
18 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Phenomix

Eligibility Criteria

Inclusion Criteria

  • •Type 2 diabetes mellitus treatment with metformin +/- TZD

Exclusion Criteria

  • •Type 1 diabetes mellitus

Arms & Interventions

4

Intervention: PHX1149

3 active, 1 placebo

Intervention: PHX1149

Outcomes

Primary Outcomes

postprandial blood glucose

Secondary Outcomes

  • fasting blood glucose, HbA1c, safety

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
A Study of Oxidative Pathways in MS FatigueFatigueProgressive Multiple Sclerosis
NCT02804594University of California, San Francisco15
Completed
Phase 2
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing DialysisAnaemia
NCT01587898GlaxoSmithKline72
Completed
Phase 2
A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 InfectionPost-Acute Sequelae of SARS-CoV-2 (PASC) InfectionCOVID-19Long COVIDLong Haul COVID
NCT05472090Tonix Pharmaceuticals, Inc.63
Completed
Phase 2
A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee OsteoarthritisKnee Osteoarthritis
NCT03122860Biosplice Therapeutics, Inc.700
Completed
Phase 2
A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of SchizophreniaSchizophrenia
NCT01234779Hoffmann-La Roche301